DOI: 10.25881/20728255_2026_21_4_S1_74

Authors

Martynov A.O., Fayzrakhmanov R.R., Shishkin M.M., Pavlovskiy O.А.

Pirogov National Medical and Surgical Center, Moscow

Abstract

Relevance. Despite the widespread use of anti-VEGF therapy, some patients with diabetic macular edema (DME) remain resistant to treatment. The spatial heterogeneity of morphological retinal changes underscores the importance of investigating the sectoral characteristics of edema regression following vitreoretinal surgery.

Purpose. To study the sectoral characteristics of macular edema regression after various types of vitreoretinal surgery in patients with treatment-resistant DME.

Materials and Methods. A total of 40 patients (40 eyes) with treatment-resistant DME were examined and divided into two equal groups. Group 1 underwent vitrectomy with internal limiting membrane (ILM) peeling, while Group 2 underwent the same procedure supplemented with subretinal hydrodissection. Retinal thickness in the parafoveal and perifoveal zones was assessed using optical coherence tomography (OCT) over a follow-up period of up to 12 months.

Results. Heterogeneity in the regression of macular edema was observed, with a more pronounced reduction in retinal thickness in the temporal sectors. In Group 2, the retinal thickness in the temporal parafoveal zone was 290.3±29.1 µm at 7 days postoperatively and 270.4±26.4 µm at 1 month–values that were statistically significantly lower than those in Group 1 (p<0.05).

Conclusion. The inclusion of subretinal hydrodissection in vitreoretinal surgery is associated with a more pronounced early anatomical response in specific sectors of the macula. Sectoral OCT analysis complements the assessment of the clinical course of refractory DME following surgical treatment.

Keywords: OCT, submacular surgery, subretinal hydrodissection, vitrectomy, DME.

References

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.

2. Panozzo G, Parolini B, Gusson E, et al. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol. 2004; 19(1-2): 13-20. doi: 10.1080/08820530490519934.

3. Nawrocka ZA, Nawrocki J. Vitrectomy in Diabetic Macular Edema: A Swept-source OCT Angiography Study. Ophthalmol Sci. 2022; 2(4): 100207. doi: 10.1016/j.xops.2022.100207.

4. Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy for diabetic macular oedema: OCT and functional correlations. Eye (Lond). 2006; 20(6): 674-80. doi: 10.1038/sj.eye.6701945.

5. Konovalova KI, Shishkin MM, Fayzrakhmanov RR. Effectiveness of multi-stage surgical treatment of proliferative diabetic retinopathy complicated by initial cataract. Bulletin of Ophthalmology. 2020; 136(6): 171-176. (In Russ.) doi: 10.17116/oftalma2020136062171.

6. Chekhonin ES, Faizrakhmanov RR, Sukhanova AV, Bosov ED. Anti‑VEGF drugs in the treatment of diabetic retinopathy. Vestnik oftal’mologii. 2021; 137(4): 136-142. [(In Russ.) doi: 10.17116/oftalma2021137041136.

7. Fayzrakhmanov R.R., Shishkin M.M., Shatalova E.O., Sukhanova A.V. Early switching from anti‑vasoproliferative therapy to a dexamethasone implant in patients with diabetic macular edema. Ophthalmosurgery. 2020;4:86-92. (In Russ.) doi: 10.25276/ 0235-4160-2020-4-86-92.

8. Bikbov MM, Fayzrakhmanov RR, Zainullin RM, et al. Macular edema as a manifestation of diabetic retinopathy. Diabetes mellitus. 2017; 20(4): 263-269. (In Russ.) doi: 10.14341/DM8328.

For citation

Martynov A.O., Fayzrakhmanov R.R., Shishkin M.M., Pavlovskiy O.А. Sectoral patterns of macular edema regression after vitreoretinal surgery for refractory diabetic macular edema. Bulletin of Pirogov National Medical & Surgical Center. 2026;21(4,supplement):74-76. (In Russ.) https://doi.org/10.25881/20728255_2026_21_4_S1_74